Literature DB >> 20462511

Differences in AMPK expression between subcutaneous and visceral adipose tissue in morbid obesity.

O Martínez-Agustin1, J J Hernández-Morante, E Martínez-Plata, F Sánchez de Medina, M Garaulet.   

Abstract

Adenine monophosphate (AMP) activated protein kinase (AMPK) is an important regulator of obesity. The objective of the present work was to study and compare AMPK protein expression in visceral vs. subcutaneous adipose tissue of morbid obese subjects and to correlate it with adipose tissue characteristics. We selected a total population of 17 extreme obese (BMI>or=40 kg/m2) aged 42.8+/-10.2 years were included in this study. We measured anthropometric and body composition parameters. Adiponectin expression by qRT-PCR, isoproterenol-stimulated lipolytic rates, and AMPK alpha subunits expression by Western blot in adipose tissue explants were determined. Finally plasma concentrations of glucose, triacylglycerols, total cholesterol, HDL-c, LDL-c and insulin were also measured. Our results showed that AMPK alpha expression was higher in subcutaneous than in visceral tissue. A positive correlation between AMPK expression and adiponectin expression in human subcutaneous adipose tissue was observed. Furthermore, a positive correlation between AMPK expression and isoproterenol evoked upregulation of lipolysis rate was also observed. In conclusion, AMPK alpha expression differed according to adipose tissue location. The positive correlation between subcutaneous adipose tissue AMPK and adiponectin or the evoked lipolysis rate could indicate a protective role of AMPK in this tissue, counteracting insulin resistance in morbid obese patients. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20462511     DOI: 10.1016/j.regpep.2010.04.008

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  5 in total

Review 1.  AMP-activated protein kinase and energy balance in breast cancer.

Authors:  Hong Zhao; Yelda C Orhan; Xiaoming Zha; Ecem Esencan; Robert T Chatterton; Serdar E Bulun
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

2.  Decreased AMP-activated protein kinase activity is associated with increased inflammation in visceral adipose tissue and with whole-body insulin resistance in morbidly obese humans.

Authors:  Marie-Soleil Gauthier; Elena L O'Brien; Sherman Bigornia; Melanie Mott; Jose M Cacicedo; X Julia Xu; Noyan Gokce; Caroline Apovian; Neil Ruderman
Journal:  Biochem Biophys Res Commun       Date:  2010-12-03       Impact factor: 3.575

Review 3.  AMP-activated protein kinase: an emerging drug target to regulate imbalances in lipid and carbohydrate metabolism to treat cardio-metabolic diseases.

Authors:  Rai Ajit K Srivastava; Stephen L Pinkosky; Sergey Filippov; Jeffrey C Hanselman; Clay T Cramer; Roger S Newton
Journal:  J Lipid Res       Date:  2012-07-13       Impact factor: 5.922

4.  Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppression.

Authors:  Yimin Shao; Geheng Yuan; Junqing Zhang; Xiaohui Guo
Journal:  Drug Des Devel Ther       Date:  2015-02-18       Impact factor: 4.162

5.  Nicotinic acid increases adiponectin secretion from differentiated bovine preadipocytes through G-protein coupled receptor signaling.

Authors:  Christina Kopp; Afshin Hosseini; Shiva P Singh; Petra Regenhard; Hamed Khalilvandi-Behroozyar; Helga Sauerwein; Manfred Mielenz
Journal:  Int J Mol Sci       Date:  2014-11-18       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.